Table 2 Pazopanib efficacy data from comparative studies
From: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
VARIABLE | STUDY | DRUGS | OUTCOME | STATISTICS |
|---|---|---|---|---|
Progression-free survival | VEG105192 [14] | Pazopanib vs placebo | 11.1 vs 2.8 months | HRa=0.40; 95% CIb: 0.27–0.60 |
COMPARZ [24] (non-inferiority) | Pazopanib vs sunitinib | 8.4 vs 9.5 months | HR = 1.05; 95% CI: 0.90–1.22 | |
International mRCC Database Consortium (IMDC) [26] | Pazopanib vs sunitinib | 8.3 vs 8.3 months | (HR = 1.08; 95% CI: 0.98–1.19) | |
Response rate | VEG105192 | Pazopanib vs placebo | 30% vs 3% | Pazopanib: 95% CI: 25.1–35.6Placebo: 95% CI: 0.5–6.4 |
COMPARZ (non-inferiority) | Pazopanib vs placebo | 31% vs 25% | p = 0.003 | |
Overall survival | VEG105192 [14] | Pazopanib vs placebo | 22.9 vs 20.5 months | HR = 0.91; 95% CI: 0.71–1.16 |
COMPARZ (non-inferiority) | Pazopanib vs sunitinib | 28.4 vs 29.3 months | HR = 0.91; 95% CI: 0.76–1.08 |